Next Article in Journal
T Cell Depleted Haploidentical Transplantation: Positive Selection
Previous Article in Journal
Fanconi Anemia - Learning from Children
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pediatric Reports
Volume 3
Issue s2
10.4081/pr.2011.s2.e15
pediatrrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Pediatric Reports is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide

by
Ashley Munchel
1,
Chimen Kesserwan
1,
Heather J. Symons
1,
Leo Luznik
2,
Yvette L. Kasamon
2,
Richard J. Jones
2 and
Ephraim J. Fuchs
2,*
1
Divisions of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
2
Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
*
Author to whom correspondence should be addressed.
Pediatr. Rep. 2011, 3(s2), e15; https://doi.org/10.4081/pr.2011.s2.e15
Submission received: 4 May 2011 / Accepted: 7 June 2011 / Published: 17 June 2011

Abstract

Allogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a potentially curative treatment option for hematologic malignancies patients who lack a suitably HLA-matched donor. The greatest challenge to performing HLA-haploidentical SCT has been high rates of graft failure and severe graft-versus-host disease (GVHD). Our group has been exploring high dose, post-transplantation cyclophosphamide (Cy) as prophylaxis of GVHD after nonmyeloablative, HLA-haploidentical bone marrow transplantation, or <i>mini-haplo</i>BMT. Among 210 recipients of mini-haploBMT, 87% of patients have experienced sustained donor cell engraftment. The cumulative incidences of grades II-IV acute GVHD and chronic GVHD are 27% and 13%, respectively. Five-year cumulative incidence of non-relapse mortality is 18%, relapse is 55%, and actuarial overall survival and event-free survivals are 35% and 27%, respectively. These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies.
Keywords: HLA-haploidentical bone marrow transplantation HLA-haploidentical bone marrow transplantation

Share and Cite

MDPI and ACS Style

Munchel, A.; Kesserwan, C.; Symons, H.J.; Luznik, L.; Kasamon, Y.L.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide. Pediatr. Rep. 2011, 3, e15. https://doi.org/10.4081/pr.2011.s2.e15

AMA Style

Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, Fuchs EJ. Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide. Pediatric Reports. 2011; 3(s2):e15. https://doi.org/10.4081/pr.2011.s2.e15

Chicago/Turabian Style

Munchel, Ashley, Chimen Kesserwan, Heather J. Symons, Leo Luznik, Yvette L. Kasamon, Richard J. Jones, and Ephraim J. Fuchs. 2011. "Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide" Pediatric Reports 3, no. s2: e15. https://doi.org/10.4081/pr.2011.s2.e15

APA Style

Munchel, A., Kesserwan, C., Symons, H. J., Luznik, L., Kasamon, Y. L., Jones, R. J., & Fuchs, E. J. (2011). Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide. Pediatric Reports, 3(s2), e15. https://doi.org/10.4081/pr.2011.s2.e15

Article Metrics

Back to TopTop